Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $45.29 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Geron Price Performance

Shares of NASDAQ GERN opened at $2.58 on Monday. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The company’s 50-day moving average is $3.11 and its 200 day moving average is $3.86. The stock has a market capitalization of $1.56 billion, a P/E ratio of -8.05 and a beta of 0.53.

Analyst Ratings Changes

Several equities analysts recently issued reports on GERN shares. Needham & Company LLC boosted their price target on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays upgraded shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. B. Riley reduced their price target on shares of Geron from $5.50 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and an average price target of $6.91.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.